Evaluation of the neuroprotective potential of optimized intranasal polydopamine nanoparticles in a lipopolysaccharide-induced rat model for Alzheimer's disease management.

Reem R Ibrahim, Abeer Salama, Samar M Abouelatta, Mona Elhabak

Abstract read

In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Reem R IbrahimDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Helwan University, Helwan, Cairo, Egypt. reemar79@hotmail.com.

Abeer SalamaPharmacology Department, National Research Centre, El- Buhouth St., Dokki, Cairo, 12622, Egypt.

Samar M AbouelattaDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ahram Canadian University, 6 October, Cairo, Egypt.

Mona ElhabakDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ahram Canadian University, 6 October, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's Disease (AD) and related dementias are on the rise globally, with forecasts suggesting that the case number will triple in the next three decades, particularly in Africa and the Middle East. This study aimed to prepare brain-targeted highly permeable intranasal polydopamine nanoparticles (PDA NPs) and to investigate their neuroprotective effect in AD. PDA NPs were fabricated via dopamine hydrochloride (DA HCl) polymerization using various safe and nontoxic surfactants to reduce particle size (PS) and enhance nasal penetration. A 4

Indexed as

Alzheimer DiseaseIndolesNanoparticlesNeuroprotective AgentsPolymersAdministration, IntranasalAnimalsBrainDisease Models, AnimalHumansLipopolysaccharidesMaleParticle SizeRatsIndolesLipopolysaccharidesNeuroprotective AgentspolydopaminePolymersAlzheimer’s diseaseBrain targetingNasal deliveryPolydopamine nanoparticlesSodium taurocholate

Identifiers

PMID41188387

DOI10.1038/s41598-025-22844-z

PMCPMC12586645

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.